<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04092868</url>
  </required_header>
  <id_info>
    <org_study_id>19CH046</org_study_id>
    <secondary_id>2019-000859-14</secondary_id>
    <nct_id>NCT04092868</nct_id>
  </id_info>
  <brief_title>Heparin Antagonization by Protamine in Cardiac Surgery: Pharmacokinetic/Pharmacodynamic Study</brief_title>
  <acronym>PICS</acronym>
  <official_title>Heparin Antagonization by Protamine in Cardiac Surgery: Pharmacokinetic/Pharmacodynamic Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Saint Etienne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Saint Etienne</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Protamine is currently used during cardiac surgery to neutralize unfractionated heparin (UFH)&#xD;
      at the end of extra-corporeal circulation (ECC). The optimal dose of protamine is currently&#xD;
      unknown, and the administration of protamine is done empirically.&#xD;
&#xD;
      Protamine and UFH pharmacokinetics are characterized by a large inter-individual variability.&#xD;
      A dose of protamine proportional to the amount of UFH administrated during the surgery may be&#xD;
      therefore not adapted to most of the patients and exposed them to a risk of under or over&#xD;
      dosage.&#xD;
&#xD;
      In this study, research investigators hypothesize that an accurate characterization of the&#xD;
      pharmacokinetic/pharmacodynamic (PK/PD) relationship of protamine may help to optimize&#xD;
      propose an optimal dosing regimen.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 13, 2019</start_date>
  <completion_date type="Actual">March 12, 2021</completion_date>
  <primary_completion_date type="Actual">March 12, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>PK/PD Protamine</measure>
    <time_frame>1 day</time_frame>
    <description>Pharmacokinetics (PK) : plasma concentration of protamine measured by liquid chromatography coupled with mass spectrometry.&#xD;
Pharmacodynamics (PD) :The effect of protamine corresponds to the kinetics of the disappearance of UFH in the blood. To do this, the investigators measure its concentration using an anti-Xa activity measurement technique.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PK/PD Protamine</measure>
    <time_frame>1 day</time_frame>
    <description>PK: evolution of protamine concentrations over time (plasma concentration of protamine measured by liquid chromatography coupled with mass spectrometry).&#xD;
PD: ts neutralizing effect evaluated by thrombinography .</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>postoperative blood loss:</measure>
    <time_frame>1 day</time_frame>
    <description>quantities of blood loss in pleural and mediastinal drains during the first 24 hours postoperatively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ratios between the amount of UFH present at the protamine injection and the dose of protamine administered.</measure>
    <time_frame>1 day</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">70</enrollment>
  <condition>Cardiac Surgery Requiring Extracorporeal Circulation</condition>
  <arm_group>
    <arm_group_label>cardiac surgery with extracorporeal circulation</arm_group_label>
    <description>during the operation&#xD;
Intervention Blood sample :&#xD;
- Choay Heparin (pharmacokinetic) concentration: t = 5, 15, 30 minutes after the start of the heparin injection + t = 5, 30, 60 minutes after the start of extracorporeal circulation&#xD;
protamine dosage: t = 2, 5, 8, 10 and 15 min after protamine injection&#xD;
anti-X activity t = 0 before administration and at time 2, 5, 8, 10 and 15 min then at time 1, 3, 5, 6 and 7 hours after protamine injection&#xD;
thrombin generation test (TGT) activity (thrombinography) : t = 2, 5, 8, 10 and 15 min after protamine injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood samples PK/ PD protamine</intervention_name>
    <description>PK/ PD protamine</description>
    <arm_group_label>cardiac surgery with extracorporeal circulation</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        patients with cardiac surgery under CEC&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients benefiting from scheduled or emergency at the Saint-Etienne University&#xD;
             Hospital (coronary artery bypass grafting, valve replacements, aortic dissections).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with a contraindication to UFH&#xD;
&#xD;
          -  Patients with a contraindication to protamine&#xD;
&#xD;
          -  Patients requiring early resurgery.&#xD;
&#xD;
          -  Patients receiving an injection of antithrombin III.&#xD;
&#xD;
          -  Pregnant women.&#xD;
&#xD;
          -  Patient for whom aprotinin use is planned during surgery.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julien LANOISELÉE, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU SAINT-ETIENNE</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU Saint-Etienne</name>
      <address>
        <city>Saint-Étienne</city>
        <zip>42055</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>September 9, 2019</study_first_submitted>
  <study_first_submitted_qc>September 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 17, 2019</study_first_posted>
  <last_update_submitted>March 25, 2021</last_update_submitted>
  <last_update_submitted_qc>March 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Protamines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

